GALECTIN THERAPEUTICS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
GALECTIN THERAPEUTICS INC. (GALT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.05 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.05, a 147.97% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.23, a 30.90% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.78, a 60.36% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.11, a 43.94% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.23, a 33.87% decline from fiscal 2024.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.86, a 57.63% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.18, a 32.57% decline from fiscal 2022.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.75, a 26.78% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.05 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $3.05 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $1.23 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $1.23 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $1.23 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $1.23 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $1.86 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $1.86 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $1.81 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $1.78 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $1.18 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.18 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $1.11 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $1.11 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $1.75 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $1.84 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $1.84 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $1.98 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $2.39 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $2.31 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $2.20 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $2.11 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $2.51 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $2.51 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $2.47 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $2.47 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $4.72 10-K · filed 2021-03-31 | |||
| 2019-09-30 | $4.72 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $4.72 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $4.72 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $5.01 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $5.02 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $5.02 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | $5.87 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | $2.39 10-K · filed 2019-03-06 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $0.97 10-K · filed 2018-03-29 | |||
| 2016-09-30 | $1.37 10-Q · filed 2016-11-08 | |||
| 2016-06-30 | $1.37 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $1.37 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $3.23 10-K · filed 2017-03-28 | |||
| 2015-09-30 | $3.23 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $3.45 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $3.45 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $12.72 10-K · filed 2016-03-15 | |||
| 2014-09-30 | $12.72 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $13.38 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $13.38 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | $3.89 10-K · filed 2016-03-15 | |||
| 2013-09-30 | $3.89 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $3.42 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $3.36 10-Q · filed 2013-05-10 | |||
| 2012-12-31 | $2.13 10-K · filed 2015-03-18 | |||
| 2012-09-30 | $2.16 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | $2.08 10-Q · filed 2012-08-10 | |||
| 2011-12-31 | $7.02 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |